KFA
RIGL icon

Kelleher Financial Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Kelleher Financial Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$23K – 116
2022
Q3 		$23K Hold
2,000
– – 0.02% 114
2022
Q2 		$22K Hold
2,000
– – 0.01% 134
2022
Q1 		$59K Sell
2,000
-8,000
-80% -$217K 0.03% 115
2021
Q4 		$265K Hold
10,000
– – 0.14% 105
2021
Q3 		$363K Hold
10,000
– – 0.16% 113
2021
Q2 		$434K Hold
10,000
– – 0.24% 71
2021
Q1 		$342K Sell
10,000
-1,300
-12% -$51.5K 0.22% 76
2020
Q4 		$395K Hold
11,300
– – 0.3% 69
2020
Q3 		$271K Buy
+11,300
New +$277K 0.22% 75

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kelleher Financial Advisors's RIGL Position: Q4 2022 in Review

Kelleher Financial Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 2,000 shares — an estimated $23K sold.

Kelleher Financial Advisors first reported a position in RIGL in Q3 2020 and held it in 9 quarters. The position peaked at $434K in Q2 2021. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

  • Kelleher Financial Advisors reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Kelleher Financial Advisors sold 2,000 Rigel Pharmaceuticals shares in Q4 2022, an estimated $23K.
  • Kelleher Financial Advisors first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 9 quarters.
  • Kelleher Financial Advisors's Rigel Pharmaceuticals position peaked at $434K in Q2 2021.
  • 118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Kelleher Financial Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.